DBV Technologies S.A. (DBVT) community

DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 6/30

$11.43−0.45 (-3.79%)

Close on Nov 12, 2026Market cap $718.69MP/E –Yield –

Community

Notes and questions about DBV Technologies from other investors

No posts about DBVT yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in DBV Technologies's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Jun 7, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DBVT.

Compare: DBVT vs ATRA · DBVT vs FATE · DBVT vs TCRX · DBVT vs MOLN · DBVT vs ELOX

Revenue growth-31.6% · median -38.4%

Operating margin-5431.6% · median -2246.8%

Net margin-5405.3% · median -2219.2%

Company	Revenue	Growth
TCRX	$5.19M	-38.4%
FATE	$4.75M	-33.4%
ATRA	$3.97M	-97.4%
DBVT	$3.84M	-31.6%
MOLN	–	–
ELOX	–	–

Company

Next earnings (est.): Mar 25, 2027, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 125
Auditor: Deloitte & Associes
SEC CIK: 1613780

Advertisement
300 × 250

See a number that looks wrong?